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Background: Erdheim-Chester Disease (ECD), a non Langerhans’ cell histiocytosis of orphan nature and propensity
for multi-systemic presentations, comprises an intricate medical challenge in terms of diagnosis, treatment and
complication management.
Objectives: The objectives are to report the clinical, radiological and pathological characteristics, as well as cardinal
therapeutic approaches to ECD patients and to provide clinical analyses of the medical chronicles of these complex
patients.
Methods: Patients with biopsy proven ECD were audited by a multi-disciplinary team of specialists who formed a
coherent timeline of all the substantial clinical events in the evolution of their patients’ illness.
Results: Seven patients (five men, two women) were recruited to the study. The median age at presentation was
53 years (range: 39 to 62 years). The median follow-up time was 36 months (range: 1 to 72 months). Notable ECD
involvement sites included the skeleton (seven), pituitary gland (seven), retroperitoneum (five), central nervous
system (four), skin (four), lungs and pleura (four), orbits (three), heart and great vessels (three) and retinae (one).
Prominent signs and symptoms were fever (seven), polyuria and polydipsia (six), ataxia and dysarthria (four), bone
pain (four), exophthalmos (three), renovascular hypertension (one) and dyspnea (one). The V600E BRAF mutation
was verified in three of six patients tested. Interferon-α treatment was beneficial in three of six patients treated.
Vemurafenib yielded dramatic neurological improvement in a BRAF mutated patient. Infliximab facilitated pericardial
effusion volume reduction. Cladribine improved cerebral blood flow originally compromised by perivenous lesions.
Conclusions: ECD is a complex, multi-systemic, clonal entity coalescing both neoplastic and inflammatory elements
and strongly dependent on impaired RAS/RAF/MEK/ERK signaling.
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Erdheim Chester disease (ECD) is a rare type of non Lang-
erhans cell histiocytosis [1,2]. It is chiefly characterized by
the migration and infiltration of lipid laden CD68(+),
CD1a(-) histiocytes to various target organs resulting in
the disruption of tissue architecture and fibrosis, thus
causing impaired organ function and often bone pain [3].
Among different individuals, this condition may manifest* Correspondence: shoenfel@post.tau.ac.il
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available in this article, unless otherwise statedin a heterogeneous spectrum of severity ranging from a
mild to a life threatening disease [4]. Different patients
may also present with an assortment of symptoms correl-
ating with their specific sites of infiltration. However, up
to 96% of patients exhibit radiological involvement of the
skeleton [5]. While 99mTc bone scintigraphy and positron
emission tomography/computed tomography (PET/CT)
are commonly used in the diagnosis of ECD, bone mag-
netic resonance imaging (MRI) may serve as a sensitive
and valuable tool in the evaluation of cancellous bone in-
volvement [6]. Apart from the skeletal system, other sites
of involvement include the central nervous system [7-11],td.; licensee BioMed Central Ltd. This is an Open Access article distributed under
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http://www.biomedcentral.com/1741-7015/12/221heart and great vessels [12-15], lungs [16-18], kidneys and
retroperitoneum [19-23], adrenal glands [24], skin [25-27],
gastrointestinal tract [28-31], breast [32-34], skeletal
muscle [32,35], thyroid and testis [36]. Hemophagocytosis
was also documented in the context of ECD [37]. Involve-
ments of the central nervous system (CNS) and cardiovas-
cular systems, in particular, were reported to be associated
with an overall poor prognosis [38]. This is important to
emphasize since the cardiovascular manifestations of ECD
are frequently overlooked [39]. Although the mean age of
diagnosis among ECD patients is 55 [5], pediatric cases
have been documented [40-44]. To date, the etiology of
ECD remains unknown and its pathogenesis, poorly
understood. Much debate has arisen relating to the clonal-
ity of ECD [45-48]. On the one hand, it is well established
that ECD is a phenomenon involving a dominant Th1 im-
mune response, suggesting a dysregulated, inflammatory
mechanism [49]. On the other hand, the V600E BRAF
mutation recently identified in 54% of the patients [50] ne-
cessitates a precursor cell harboring this somatic mutation
and, thus, a clonal neoplastic origin. A novel approach is
described by Berres et al., who suggest that ECD is an
example of an ‘inflammatory myeloid neoplasm’ [51]. The
fitting therapeutic roadmap for the ECD patient is a
complex mosaic of various clinical elements [52,53]. A di-
verse compilation of pharmacology has been under inves-
tigation over the past years in an attempt to strike at
the Achilles heel of the disease. Currently, interferon-α is
the sole agent which has demonstrated an increase in
survival and is, thus, considered the first line of treatment
[14,38,54-56]. Various second line treatments exist. Ana-
kinra, an interleukin-1 receptor antagonist is suitable for
mild disease [13,40,57-59]. Infliximab, an anti TNF-α
monoclonal antibody has shown efficacy in the treatment
of the cardiovascular involvement of ECD [60]. Vemurafe-
nib, a small molecule which inhibits the V600E mutated
BRAF protein, was found to induce remarkable responses
among patients who harbor that mutation [61,62]. Finally,
cladribine may be a reasonable therapeutic alternative for
patients with moderate to severe disease who failed previ-
ous second line regimens [63-66]. Other treatments in-
clude various types of chemotherapeutic agents [67-70],
radiation therapy [71-74], steroids [38,54,70,75], bispho-
sphonates [76-78] and bone marrow transplantation
[79,80]. The prognosis of ECD is poor. Most patients suf-
fer from progressive morbidity, which may relate to both
the disease itself and its treatments. As for mortality,
according to the largest series published, the one- and
five-year survival rates of ECD patients are 96% and 68%,
respectively [38].
Patients and methods
Seven patients (five men, two women) were recruited to
the study from six different medical centers in Israel(Table 1). Of these seven patients, five are discussed in
detail. Each patient was evaluated and audited according
to his/her disease distribution. Patients were included
in this study subsequent to meeting the following inclu-
sion criteria: first, a pathological confirmation was ob-
tained only after the identification of CD68(+), CD1a(-)
histiocytes in a biopsy specimen harvested from a locus
of clinical interest. Second, a thorough, professionally
performed workup of the patient was completed. This
workup must have included a detailed anamnesis and a
meticulous physical examination. Laboratory investiga-
tions must have included at least one complete blood
count and one full blood chemistry panel. In regards to
imaging, the patient must have undergone at least one
CT scan of the thorax, abdomen and pelvis and one
brain MRI. Cardiac MRI was performed only in patients
suspicious of cardiovascular involvement on the basis of
suggestive symptoms or prior imaging. As for nuclear
medicine, at least one 99mTc bone scintigraphy or one
fluorodeoxyglucose (FDG) PET scan must have been
performed. Molecular analyses of the BRAF oncogene
were performed in six of the seven patients using digital
PCR amplification followed by sequencing of the ampli-
fied segments using either Sanger’s sequencing tech-
nique or pyrosequensing, depending on the medical
center in which each examination was performed.
Case reports
Patient #1: a longstanding disease with multiple system
involvement and a dramatic response to vemurafenib
A 39 year-old woman of Turkish-Iraqi descent presented
in September 2007 to the emergency department with
low grade fever, signs of weakness and difficulty walking
due to diffuse bone pain mostly in the knees and both
pectoral and pelvic girdles. Shortly before her admission
the patient began experiencing alternating hot flashes
and cold bouts disproportionate to the weather or cloth-
ing and suffered from frequent night sweats. Approxi-
mately six months prior to this incident, fatigue and leg
pain slowly developed. The pain originally began as a
tingling sensation, accompanied by paresthesia. It had
escalated over several months and progressed to fully
fledged bone pain. At the time of presentation, the pain
was described as initiating at rest and constant, occa-
sionally accompanied by episodes of fever. The patient
was admitted for several consecutive hospitalizations.
Upon inspection of her face, both exophthalmos and
yellowish peri-orbital xanthelasmae-like lesions were ap-
parent. The remainder of her physical examination was
unremarkable, without deformation or bony swelling
and without neurological deficits. It is noteworthy that
the patient was polydypsic and polyuric for approxi-
mately five years prior to the onset of bone pain, con-
suming and excreting up to 12 liters of water per day.
Table 1 Characteristics of the seven ECD patients
# Age Sex Presenting sign/symptom Disease involvement sites BS CT PET/CT Brain
MRI
Heart
MRI
Treatment roadmap Notable responses
and timeframe
BRAF status
1 39 F Bone pain STN, CNS, PIT, ROS, CUT, RP, PLM, RTN + + + + - STR→ VB→ IFNa→ IFNa +
VB→ ANK→ CLD→ VMR
VMR: marked neurological
improvement in 3w
+
2 50 M Skin lesions and bone pain STN, CNS, PIT, CUT, RP, ADR, LYM + + - + - CLD CLD: regression of intracranial
perivenous lesion and neurological
stabilization, gradually over 13 m
-
3 62 F Bone pain STN, PIT, ROS, CUT, PLM, CV + + + + + STR→MTX + STR→ IFNa +
VB→ VB→ INX + MTX
INX +MTX - reduction in pericardial
effusion volume over a 2 m period
-
4 55 M Ataxia and dysarthria STN, CNS, PIT, MNG, RP - + + + - IFNa - UNK
5 53 M Ataxia and dysarthria STN, CNS, PIT, MNG + + + + - STR→ VB→ pIFN→ CLD - -
6 49 M Abdominal pain STN, PIT, ROS, RP, PLM, CV, GI + + + + + STR + VB + IFNa→ VB +
IFNa→ IFNa→ pIFNa→
VMR→ pIFNa
VMR: marked skin toxicity even at
low doses
+
7 58 M Polyuria, polydipsia and HTN STN, PIT, CUT, RP, PLM, CV + + + + + IFNa IFNa: Normalization of constitutional
symptoms over a 6 m period
+
ADR, adrenal glands; ANK, anakinra; BS, 99mTc bone scintigraphy; CLD, cladribine; CNS, central nervous system; CT, computed tomography; CUT, cutaneous involvement; CV, cardiovascular system; F, female; GI,
gastrointestinal tract; HTN, hypertension; IFNa; interferon alpha; pIFNa, pegylated interferon alpha; INX, infliximab; LYM, lymph nodes; m, month; M, male; MNG, meninges; MRI, magnetic resonance imaging; MTX,
methotrexate; PET/CT, positron emission tomography/computed tomography; PIT, pituitary gland; PLM, pulmonary system; ROS, retro orbital space; RP, retroperitoneum; RTN, retina; STN, skeleton; STR, steroids; UNK,
unknown; VB, vinblastine; VMR, vemurafenib; w, weeks.
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http://www.biomedcentral.com/1741-7015/12/221Despite this, a diagnosis of central diabetes insipidus
was established and treatment with intranasal desmo-
pressin initiated only upon hospitalization, presumably
due to the patient’s adjustment to the gradual changes in
water metabolism over the years. Apart from her known
iron deficiency anemia, laboratory studies revealed in-
creased levels of C-reactive protein (CRP: 70 mg/L) and el-
evated erythrocyte sedimentation rate (ESR: 72 mm/hour).
A broad panel of immunologic studies, including rheuma-
toid factor (RF) and anti-nuclear antibodies was unremark-
able. Negative blood and urine cultures ruled out an
infectious etiology. Protein electrophoresis (PEP) yielded
no monoclonal spike and the oncological markers were
found to be within normal limits. Further investigations
included radiography, which revealed bilateral sclerotic
changes in the femoral and tibial bones and electromyog-
raphy, which demonstrated normal muscle and nerve
functionality. A subsequent 99mTc bone scintigraphy dem-
onstrated increased tracer uptake in the superior aspect of
both orbits, the central sphenoidal region, left humeral
head, right femoral greater trochanter and lateral superior
aspect of the left iliac crest as well as diffuse, symmetric,
bilateral increased tracer uptake in the femurs and tibiae
enveloping both knees (Figure 1A). A CT of the femurs
and tibiae exhibited an irregular osseous texture demon-
strating bones riddled with mixed patchy lesions of scler-
otic and lytic nature. This was suggestive of either a
metabolic, malignant or granulomatous process. An add-
itional CT of the thorax, abdomen and pelvis revealed
congestion of both renal sinuses with slightly distended
ureters (Figure 2A). CT and later MRI of the brainFigure 1 99mTc bone scintigraphs of patients #1 (A), #2 (B), #3 (C) and
symmetric pattern of increased tracer uptake, particularly involving the fem
Despite an obvious variability in the degree of tracer uptake among patien
correlate with the degree of bone pain at the time of presentation.revealed bilateral retro-orbital nodular lesions (Figure 3A),
diffuse thickening and tortuosity of the optic nerves, en-
largement of both lacrimal glands and soft tissue fullness
of the sphenoid sinus (Figure 3C). An MRI dedicated to
the pituitary revealed no deviation from the normal anat-
omy. Over the two week period between two consecutive
hospitalizations papilledema developed, accompanied by
headaches, blurred vision and nausea. A lumbar puncture
revealed an increased opening pressure of 44 cmH2O.
Treatment with acetazolamide (250 mg X3 daily) was initi-
ated, the increased intracranial pressure normalized and
related symptoms abated. Biopsies were obtained from the
tibial bone marrow and from a lacrimal gland. A micro-
scopic examination of the tibial biopsy revealed bony tra-
beculae separated by a xanthomatous, diffuse spindle cell
macrophage population with few interspersed giant cells
(Figure 4A). The spindle cells stained relatively uniformly
for the presence of CD163, and in a more patchy fashion
but quite strongly for factor XIIIa (Figure 4C), surface
staining for CD14 and granular intense staining for CD68
(Figure 4B). CD1a and S-100 staining were globally nega-
tive (Figure 4D) except for one focus of S-100(+) cells, sug-
gesting infiltration of the marrow with Langerhans cells.
Overall, these findings were most consistent with a diagno-
sis of ECD with a component of Langerhans cell histiocy-
tosis. Over the five years pursuant to her diagnosis on May
2007, the patient was treated with several treatment proto-
cols. At first, steroids (prednisone, 60 mg/day) provided
a temporary relief - a marked decrease in bone pain,
decrease in CRP levels and normalization of fever. Two
months later vinblastine (6 mg/m2/week) was introduced#5 (D) taken prior to diagnosis. Note the characteristic bilateral
oral and tibial long bones and the periarticular regions of the knees.
ts in these series, the intensity of tracer uptake did not necessarily
Figure 2 Coronal reformatted contrast enhanced computed tomography images of patient #1, obtained at the time of the diagnosis
(A) and 4.5 years after the diagnosis (B). The latter reveals severe hydronephrosis and marked cortical thinning of the left kidney and a
peri-renal mass compressing the right kidney. Also, note the fine bilateral peri-renal infiltrate forming a ‘hairy kidney’ appearance.
Mazor et al. BMC Medicine 2014, 12:221 Page 5 of 18
http://www.biomedcentral.com/1741-7015/12/221as a steroid sparing agent. This protocol failed to evoke a
favorable long lasting response and was substituted for
treatment with interferon-α. Since then, interferon-α has
served as the primary therapeutic agent administered at
dosages as low as 3 × 106 IU X 3 times weekly and as high
as 6 × 106 IU X 5 times weekly. Initially, interferon-α was
administered as a single agent. Later on, it was comple-
mented by vinblastine (8 mg/1 to 4 months) and by pami-
dronic acid (60 mg/1 to 3 months) in order to better
control the lytic lesions. It is noteworthy that this patient
continued to deteriorate neurologically even at the highest
doses of interferon-α administered (6 × 106 IU X 5 times
weekly). However, the addition of vinblastine to this regi-
men succeeded in stabilizing the patient clinically and
allowed for a gradual decrease in the dosage of interferon-
α to a maintenance dose of 6 × 106 IU X 2 times weekly
over a two year period. Three years after the diagnosis of
ECD, a four-month trial of anakinra (100 mg/day) was
attempted, mainly due to multifocal disease progression.
However, this agent yielded unsatisfactory results. This
attempt was followed by a five-month trial of cladribine
(0.14 mg/kg/day for five consecutive days, every four
weeks), a drug which yielded no apparent benefit to the
patient and was very poorly tolerated. By this time, the pa-
tient’s neurological symptoms, vis-à-vis her lingual and
motor capabilities, had deteriorated greatly once again.
She was markedly dysarthric and confined to a wheelchair.
Consequently, a biopsy obtained from the peri-renal mass
was attempted and found to contain ECD histiocytes
which harbor the V600E BRAF mutation. After receiving
proper counseling and signing an informed consent, treat-
ment with vemurafenib (1,920 mg/day later tapered to
960 mg/day) was initiated with no less than a spectacular
improvement. After two weeks of treatment the patientbegan to exhibit clinical improvement. Ultimately, follow-
ing treatment with this agent, the patient regained her
ability to walk distances of up to 500 meters and recovered
her ability to speak fluently.
Patient #1 - clinical analysis
Overall, the patient’s tolerance and response to treat-
ment were the prime variables taken into consideration
in the formulation of her therapeutic roadmap. Since the
initial presentation of symptoms and throughout the dif-
ferent therapeutic lines, several significant radiological
and clinical events had occurred.
First and foremost, following treatment with interferon-
α, the patient experienced complete resolution of the bone
pain. Nevertheless, consecutive CT and PET/CT scans re-
vealed deterioration of the osteosclerotic processes in the
long bones as well as intense bilateral periarticular tracer
uptake indicative of an active disease (Figure 5A,B). This
was further substantiated by a gradual increase in bone
density as shown on annual DXA (duel energy x-ray ab-
sorptiometry) assays aimed at assessing the bone density
of the femurs, pelvis and spine.
Second, one year following diagnosis, the retro-orbital
lesions achieved maximal size (Figure 3A), with one le-
sion protruding extraconaly through the inferior orbital
fissure causing inferior displacement of the orbit. The
severe clinical progression necessitated the initiation of
an aggressive combination treatment protocol compris-
ing high dose interferon-α (9 × 106 IU X 3 times weekly),
vinblastine (8 mg/month) and pamidronic acid (60 mg/
month). This treatment protocol resulted in marked re-
gression of the retro-orbital lesions and was clinically
evident by normalization of the exophthalmos and im-
provement of visual acuity (Figure 3B). The treatment
Figure 3 Various intracranial MRI findings of patients #1, #2 and #4. Coronal T1 weighted, gadolinium enhanced MR images of the retro-bulbar regions of
patient #1 one year following diagnosis (A) and 4.5 years after diagnosis (B). The former (A) demonstrates bilateral nodular masses located at the superior
lateral aspect of the retro-orbit. These masses involve both the lacrimal glands and superior rectus muscles and undergo heterogeneous enhancement following
gadolinium administration. The latter (B) demonstrates a marked reduction in the size of these lesions, presumably due to treatment with interferon-α. (C) Coronal
T1 weighted, gadolinium enhanced MR image of patient #1 showing mucosal thickening in the sphenoidal sinus as well as soft tissue fullness which undergoes
enhancement following gadolinium administration. This finding is also apparent in patient #4 (F), who also exhibits an extra axial enhancing lesion situated
in the vicinity of the planum sphenoidale (E). In SWI sequence, both patients #4 (D) and #2 (G) exhibit multiple punctate hypointensities in the basal ganglia.
These patterns are not typical for senile calcifications. Patient #2 also exhibits infiltrative enhancing tissue which narrows the transverse left sinus, adjacent to
the falx and tentorium (I). The same tissue is seen displacing the superior sagittal sinus (H). MR, magnetic resonance; SWI, susceptibility weighted imaging.
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Figure 4 Histological sample from the tibia of patient #1. (A) H&E. Bony trabeculae separated by fibrosis and sheets of foamy macrophages.
(B) Histiocytes demonstrating intense granular staining for CD68. (C) Histiocytes demonstrating patchy staining for factor XIIIa. (D) S-100 protein
staining of the biopsy specimen.
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fullness that originally developed inside the sphenoidal
sinus. However, in parallel to the regression of the le-
sions mentioned above, new lesions have begun develop-
ing in concert with the interferon-α treatment. These
new lesions appeared to be bilateral and to involve the
cerebellar peri-dentate region, the middle cerebellar pe-
duncles and the white matter of the pons (Figure 6A-C).
Three years after her diagnosis, the patient’s ataxia and
dysarthria progressed markedly.Third, frequent fundoscopies were performed due to
the patient’s tendency to develop papilledema in con-
junction with episodes of increased intracranial pressure.
Four years following diagnosis, new sub-choroidal le-
sions involving the macula densa appeared on fundos-
copy of both eyes (Figure 7A-B). These findings were
even more visible on red free imaging produced by a
blue wavelength confocal scanning laser ophthalmoscope
(Figure 7C-D). These findings proved to be stable on a
neuro-ophthalmological follow up performed two years
Figure 5 PET and CT findings of the lower limbs of patients #1 and #3 (A) Positron emission tomography showing symmetric, bilateral,
abnormally increased intra-medullary uptake of fluorodeoxyglucose in the femurs and tibiae of patient #1 approximately 4.5 years following diag-
nosis. (B) Computed tomography of the femurs and tibiae of patient #1 at the time of diagnosis, exhibiting periostitis as well as diffuse, irregular
intra-medullary sclerosis. These bones are riddled with mixed patchy lesions of sclerotic and lytic nature encased in a markedly thickened cortex.
(C) Similar findings can be observed in the computed tomography of patient #3.
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disturbances of patient #1 were attributed to increased
intracranial pressure while those that appeared later,
were attributed to these subchoroidal lesions.
Fourth, despite aggressive treatment, over the five-year
period since diagnosis infiltration of the retroperitoneum
had occurred with formation of a mild, bilateral ‘hairy
kidney’ appearance on CT (Figure 2B). The left kidney
underwent severe hydronephrosis with marked cortical
thinning and the right kidney became compressed by a
peri-renal mass. It is noteworthy that this mass was
characterized by an increased tracer uptake on PET/CT.
Globally, at the time of follow up, renal function is pre-
served with creatinine levels within normal limits.
Overall, a five-year follow up reveals favorable re-
sponses to treatment with interferon-α in terms of bone
pain amelioration and regression of the retro-orbital le-
sions (Figure 3B). However, this agent had little effect on
the retroperitoneal, central nervous system and ophthal-
mological involvements of the disease. Ultimately and
most importantly, the patient exhibited dramatic im-
provement in neurological function following her treat-
ment with vemurafenib.
Patient #2: a cutaneous presentation with intracranial
perivenous involvement responding to cladribine
A 50-year-old man of Iraqi descent presented to an out-
patient dermatology clinic in September 2010, complaining
of asymptomatic skin lesions which had been recurringand remitting over the past seven years (Figure 8B). Upon
an elaborated history, the patient disclosed suffering
from mild lower limb pain, loss of libido and increased
thirst and urination for the past seven years, as well. On
examination, 10 red-yellow papules, 4 to 8 mm in size,
were observed over his trunk and extremities. Labora-
tory findings revealed decreased levels of testosterone
(3 nmol/L), lutenizing hormone (LH) (0.3 mIU/mL) and
follicle-stimulating hormone (FSH) (0.4 mIU/mL). A
24 hour urine collection concluded in increased urine
volume (3.2 L) and decreased urine osmolality. These
findings led to the diagnosis of central diabetes insipi-
dus and hypogonadotropic hypogonadism; thus, the pa-
tient initiated treatment with intranasal desmopressin
and monthly intramuscular injections of choriogonado-
tropin alfa. Other laboratory tests including a complete
blood count, thyroid hormones, lipid profile, viral serol-
ogies, protein electrophoresis, purified protein deriva-
tive (PPD), angiotensin-converting enzyme (ACE) and
tumor markers were without pathological findings. Sev-
eral imaging studies were conducted. Plain radiography
demonstrated marked osteosclerosis of the tibiae and
fibulae. A 99mTc bone scintigraphy revealed intense
symmetric bilateral uptake of tracer in the diametaphy-
seal regions of the distal femurs and proximal tibiae
(Figure 1B). A brain MRI demonstrated thickening of
the pituitary stalk and several cluster-like nodular enhan-
cing lesions involving the left cerebellum in close proxim-
ity to the fourth ventricle (Figure 6D,E). Also, multiple
Figure 6 Cerebellar MRI findings of patients #1, #2 and #4 Axial T2 weighted MR images of patient #1 at the level of the cerebellum, middle
cerebellar peduncles and pons taken at the time of diagnosis (A) one year following diagnosis (B) and four years following diagnosis (C). Note
the bilateral hyperintense signals which emerged one year following diagnosis in the pons and peri-dentate regions as well as in the left middle
cerebellar peduncle (B). The signal intensity of these processes seems to have decreased during the following three years (C). (D) An axial T2
weighted MR image of patient #2 at the level of the cerebellum demonstrating a unilateral focus of hypointense signal at the left peri-dentate
region. (E) This cluster like lesion is better accentuated in SWI sequence. (F) An axial T2 weighted MR image of patient #4 displaying multiple,
bilateral, diffuse foci of hyperintense signals involving the brainstem and peridentate areas. Another abnormal finding, adherent to the dura of
Meckel’s cave, exhibits radiological similarity to a meningioma. Note the variable MR manifestations of cerebellar lesions in different ECD patients.
ECD, Erdheim Chester disease; MR, magnetic resonance; SWI, susceptibility weighted imaging.
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in SWI sequence (Figure 3G). This pattern is not typical
of senile calcifications. The most prominent finding in
this patient’s workup was that of intracranial soft tissue
infiltrating posterior to the confluence of sinuses and
sheathing the superior sagittal and left transverse sinus
(Figure 3H-I). A whole body CT scan showed infiltration
of the perirenal fat and bilateral enlargement of the ad-
renal glands. Three biopsies were eventually conducted:one of a skin lesion and two bone marrow biopsies.
Surprisingly, both of the bone marrow biopsies exhibited
normal bone marrow. However, the skin biopsy revealed
histiocytes of varied morphology embedded in a lympho-
cytic infiltrate. The histiocytes stained positive for CD68
and negative for CD1a and Factor XIIIa. Electron micros-
copy of the specimen showed clusters of lipid droplets,
with no evidence of Birbeck granules. These pathological
findings were supportive of the diagnosis of ECD. Since
Figure 7 Fundoscopy of patient #1. Fundoscopy images of the right (A) and left (B) eyes of patient #1, demonstrating sub choroidal lesions
involving the macula densa. (C,D) Red free imaging produced by a blue wavelength confocal scanning laser ophthalmoscope demonstrating the
extent of these lesions in the right (C) and left (D) eyes.
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several occasions, exhibiting a repertoire of signs and
symptoms. Among them were both constitutional and
neurological symptoms. The various emerging phenomena
included episodes of increased intracranial pressure with
papilledema, ataxia, dysarthria, pathological crying andFigure 8 Skin lesions of patients #2 and #3. (A) Yellowish periorbital xa
size, over the right flank of patient #2.laughing, hyper-reflexia and nystagmus. The variety of
these symptoms prompted a more thorough evaluation of
cerebral blood flow. Both CT venography and later MR
venography demonstrated attenuated flow in the superior
sagittal sinus due to external compression on the vessel,
displacing it from the skull. Also, a complete collapse ofnthelasma-like lesions in patient #3. (B) A red yellow papule, 8 mm in
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following the diagnosis the patient was treated with
monthly four to five day courses of cladribine IV, ad-
ministered intravenously at dosages of 4.5 to 4.8 mg
daily (0.07 mg per kg of body weight daily). The patient
received a total of 13 courses of cladribine, which re-
sulted in a significant improvement in his fatigue and
weakness. In addition, a decrease in the episodes of
papilledema and stabilization of his neurological symp-
toms were noted along with an evident radiological de-
crease in the amount of infiltrative tissue compressing
the superior sagittal sinus.
Patient #2 - clinical analysis
Several key issues should be addressed in the analysis of
this patient. First, this patient exemplifies how elusive the
diagnosis of ECD can be. He originally sought medical
attention in an outpatient clinic to investigate his recur-
ring dermatological lesions. A thorough workup which
originated in a detailed history performed by his physi-
cians succeeded to lift the veil off the relatively subtle
symptoms that were evident in the initial phases of his
disease and to associate them with his skin lesions.
Second, in this particular case, an extra-axial, perivascu-
lar intracranial process appears to impair the cerebral
blood flow, causing both chronic indolent damage as well
as acute flare-ups of increased intracranial pressure. It
may very well be that this patient’s neurological symptoms,
originate both from global oxygen deprivation as well as
focal disease-associated lesions. This is evident due to
the nature of this patient’s symptoms, as he exhibits signs
of upper motor neuron impairment and episodes of in-
creased intracranial pressure alongside pseudobulbar and
cerebellar syndromes. Additionally, treatment induced le-
sion regression seems to slightly alleviate and stabilize the
global neurological impairment while the focal deficits re-
main unchanged.
Third, one must consider that several biopsies may be
needed to harvest a satisfactory specimen. Thus, a nega-
tive biopsy should not exclude a working diagnosis of
ECD in otherwise highly suggestive settings.
Finally, this patient received prolonged treatment with
lower doses of cladribine in an attempt to control his
CNS involvement. Although considered an advanced
line treatment in ECD, this treatment strategy appears to
have resolved this patient’s constitutional symptoms and
caused regression of the lesions sheathing his intracra-
nial vasculature.
Patient #3: a case of severe cardiovascular involvement
stabilized by treatment with infliximab
A 55-year-old woman of Algerian descent presented to
our medical center in August 2008 with a chief com-
plaint of worsening bone pain. She began suffering froma mild degree of diffuse bone pain 13 years ago. The
pain was described as constant and as affecting her lum-
bar spine, knees, pelvic bones and feet. The pain was
managed rather well until her time of presentation using
non-steroidal anti-inflammatory drugs. At the time of
presentation, the pain had intensified to a degree which
prevented her to stand from a sitting position. The pa-
tient had a past medical history of diabetes insipidus for
which she was diagnosed 12 years prior to her current
presentation and also suffered from recurrent urinary
tract infections. Her physical examination was unre-
markable aside from periorbital xanthelasma-like lesions
(Figure 8A). Abnormal laboratory findings included a
microcytic iron deficiency anemia (hemoglobin: 11 g/dL,
MCV: 77.5 fL, iron: 19 μg/dL) and an elevated ESR
(98 mm/hr). Both protein electrophoresis and tumor
markers were without pathological findings. A radio-
graph of the lower limbs was obtained and demonstrated
bilateral involvement of the femurs and tibiae with cor-
tical and periosteal thickening accompanied by a mixture
of lytic and sclerotic lesions. These findings were even
more apparent on CT (Figure 5C). A 99mTc bone scintig-
raphy revealed a multifocal bone disease characterized
by bilateral, symmetric increased tracer uptake involving
both tibiae, distal femurs and iliac bones. Also, an asym-
metric increased tracer uptake was noted in both of the
upper limbs, favoring the right humerus, radius and ulna
(Figure 1C). A CT guided biopsy of the right femur was
performed. The specimen included cores of long bone
showing focal fibrosis, foamy histiocytic infiltrate, in-
flammatory cells, giant cells and reactive cortical scler-
osis. The histiocytes described were found to be CD68
positive and CD1a negative, a histological picture com-
patible with ECD. After her diagnosis was established in
December 2009, the patient was treated with prednisone
at an initial dosage of 60 mg/day which underwent grad-
ual tapering to 5 mg/d over a period of one year. Five
months after the initiation of prednisone, methotrexate
was introduced at escalating dosages of 10 to 25 mg/week.
This treatment protocol was successful in generating a
transient decrease in bone pain which lasted for two years.
However, during that period of time, the patient began
experiencing extraskeletal symptoms: alternating hot
flashes and cold bouts, blurred vision, headaches, nau-
sea and vomiting. Last but not least, the patient’s most
prominent complaint was dyspnea, as she suffered from
frequent episodes of shortness of breath following even
the slightest of physical efforts, rendering her unable to
walk more than 100 meters. Assessment of the patient’s
CNS included a brain MRI which was without patho-
logical findings. The patient’s cardio-pulmonary evaluation
included several echocardiography studies which revealed
recurrent pericardial effusions of moderate to large pro-
portions with associated fibrin. Contrast enhanced CT of
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aorta’) of the aortic root as well as infiltration of the medi-
astinum adjacent to the right atrium and also confirmed
the existence of a small loculated pleural effusion. In
addition to the known pericardial effusion, gadolinium
enhanced cardiac gated MRI revealed thickening of the
pericardium, thickening of the wall of the ascending aorta
(of up to 10 mm) and several lesions encasing the right
atrium, right coronary artery and superior vena cava.
These findings were also apparent on a whole body PET/
CT scan which demonstrated increased tracer uptake in
the lesions encasing the great vessels as well as in the osse-
ous foci consistent with the former 99mTc bone scintig-
raphy. Due to the multifocal progression of her disease,
the patient was started on a combination therapy regimen
of interferon-α (3 × 106 IU X2 to 3/week) and vinblastine
(6 mg/m2/week). However, this regimen was tolerated very
poorly by the patient, as she became severely neutropenic
with an absolute neutrophil count of less than 500 cells/μL.
The dual interferon-α - vinblastine regimen was conse-
quently stopped after four weeks of treatment and replaced
with vinblastine as a single agent regimen at a dosage of
6 to 8 mg/m2/week. Nevertheless, even this treatment
was poorly tolerated and, thus, was stopped following
an additional eight weeks of therapy. In parallel, the
patient was tested for the V600E BRAF mutation and
was found to be negative. Ultimately, a combination
therapy regimen of infliximab (5 mg/kg/6 weeks) and
methotrexate (20 mg/week) was initiated. Following six
courses of treatment the patient improved clinically,
with a notable decrease in the frequency and intensity
of her pain, nausea and dyspnea. A marked reduction in
the proportion of the pericardial effusion was noted on
both echocardiography and computed tomography. How-
ever, despite treatment, the mediastinal lesions were found
to be metabolically active on PET/CT and no reduction
in their size was evident on CT. Most interestingly, this
treatment resulted in better control of the patient’s dia-
betes insipidus, necessitating a decrease in the dosage of
desmopressin.
Patient #3 - clinical analysis
This patient, who suffers from ECD with a prominent cardio-
vascular component, presents several medically noteworthy
insights. First, recurrent, moderate to large pericardial
effusions comprise a worrisome medical phenomenon.
These effusions raise questions regarding the potential fu-
ture compromise of cardiac function in the face of rapid
effusion volume fluctuations. Therefore, we recommend
that ECD patients with substantial pericardial effusions
should be monitored frequently using echocardiography
and assessed for potential pericardiocentesis should
significant cardiac compromise occur. The architecture of
the mediastinal lesions, their size and location, are importantvariables when considering invasive interventions. In pa-
tients with extensive cardiovascular involvement, cardiac
MRI may serve as the modality of choice in monitoring
their complex mediastinal anatomy [12]. Overall, ECD as-
sociated encasement of the cardiac and/or mediastinal
blood vessels should be monitored with caution for poten-
tial signs of stenosis. For example, in this patient, the
superior vena cava and right coronary artery are involved
and, thus, a high index of suspicion should remain with
respect to potential emergencies involving these vessels.
Compromised flow in the superior vena cava (vis-à-vis the
superior vena cava syndrome) could cause both cerebral
and vocal cord edema, manifesting as hoarseness and fa-
cial edema alongside superficial venous distention on the
neck and upper trunk. In this patient, treatment with
infliximab succeeded in greatly reducing the volume of the
effusion and, thus, improved the patient’s clinical status.
As for her prior treatment regimen, we concluded that
low dose methotrexate may be a reasonable treatment al-
ternative in selected cases of mild disease free of extraske-
letal manifestations, as this patient benefited from it for
two pain controlled years. Conversely, steroids are no lon-
ger recommended as a first line of treatment for ECD.
Patients #4 and 5: two cases of an atypical, painless
presentation of ECD with intracranial involvement
refractory to interferon-α
Patient #4
A 62-year-old man of Yemenite descent presented with
a myriad of symptoms which underwent gradual wors-
ening over the year prior to his evaluation in our med-
ical facility in February 2012. Among his complaints
were marked fatigue and weakness, difficulty speaking,
disturbance in balance and depression. His past medical
history included hypertension and type II diabetes melli-
tus. In addition, he was diagnosed ten years prior to our
evaluation with diabetes insipidus, for which he was
treated with nasal desmopressin. In the process of diag-
nosing diabetes insipidus, the patient underwent a brain
MRI which revealed multiple meningioma-like lesions as
well as a finding suspected to be a demyelinating pon-
tine lesion. Since no neurological deficits were identified,
the patient remained under surveillance until one year
prior to our evaluation, when he began suffering from
insidious pseudo-bulbar and cerebellar syndromes. His
neurological examination revealed ataxia, dysarthria,
dysmetria and dysdiadochokinesia. Laboratory findings
included a microcytic anemia, with a mean corpuscular
volume (MCV) of 64.8 fL. A brain MRI revealed three
meningiomas, an olfactory meningioma, a frontal men-
ingioma adjacent to the planum sphenoidale (Figure 3E)
and a meningioma of the dura encasing the posterior as-
pect of the cavernous sinus, in the vicinity of Meckel’s
cave. The scan also showed unenhanced, heterogeneous
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clei (Figure 6F) as well as thickening of the infundibu-
lum accompanied by the absence of signal from the
posterior pituitary. In addition, similar to patient #2, this
patient exhibited a pattern of multiple punctate hypoin-
tensities involving the basal ganglia in SWI sequence
(Figure 3D). These accumulated findings raised the pos-
sibility of a histiocytic disorder and, thus, prompted a
PET/CT scan. The whole body PET/CT scan showed in-
creased symmetric bilateral tracer uptake in the bones of
the lower limbs. These bones demonstrated a patchy
pattern of mixed lytic and sclerotic lesions. On CT, an
abnormal appearance of the kidneys was noted and
interpreted as infiltration of soft tissue into the region of
the renal pelvises. Two biopsies were obtained from the
tibial bones. The first bone marrow biopsy demonstrated
a normocellular trilineage marrow with no evidence of
histiocytosis. Only the second biopsy revealed fibrotic
bone marrow lacking hematopoietic cells with clusters
of CD68(+), foam cells as well as a mild to moderate
mononuclear infiltrate. Several multi-nucleated giant
cells were noted. Stains for CD1a and S-100 were nega-
tive. These findings were consistent with ECD. Following
his diagnosis in May 2012, the patient began treatment
with interferon-α at dosages of 1 to 3 million IU three
times weekly. Despite the low dosages, this treatment
was poorly tolerated. Over the 15 months period since
his diagnosis was established, the patient’s disease pro-
gressed indolently. Shortly after, his neurological mani-
festations began deteriorating rapidly. In parallel, his
performance status declined markedly, he became bed-
ridden and succumbed to his disease three months after,
an overall 18 months following his diagnosis.
Patient #5
A 53-year-old man of Libyan descent sought medical at-
tention in November 2012 due to deterioration in his
walking stability as well as slowing of his speech. Appar-
ently, these symptoms slowly progressed over a period of
approximately 18 months prior to this patient’s presenta-
tion. Upon a detailed history, the patient disclosed suffer-
ing from polyuria and polydipsia for the last 7.5 years. A
prior medical investigation aimed at identifying the cause
of these symptoms was concluded as non diagnostic. His
neurological examination revealed dysarthria, dysmetria,
gait instability and a multidirectional gaze evoked nystag-
mus. Also, decreased left flank muscle tone and lower
limb hyporeflexia were noted. A fundus examination was
unremarkable. Aside from a mild normocytic anemia
(hemoglobin: 12.4 mg/dL, MCV: 86.6 fL), other laboratory
studies, including a lumbar puncture, were without signifi-
cant findings. Laboratory studies aimed at identifying viral
serologies and paraneoplastic antibodies were negative.
The conjunction of this patient’s cerebellar syndrome,polyuria and polydipsia raised a suspicion of a histiocytic
disorder. A 99mTc bone scintigraphy study was conducted
and revealed bilateral, abnormally increased tracer uptake
in the distal femurs and both proximal and distal tibiae
(Figure 1D). A brain MRI uncovered several abnormal
findings, including a pontine lesion, mild cerebellar at-
rophy, absence of the posterior pituitary and a parietal
parasagittal extra-axial lesion 23 mm in diameter, con-
sistent with a meningioma. A whole body PET/CT scan
was conducted and disclosed an increased tracer uptake
in the pons, as well as the femurs and tibiae. The PET
findings in the long bones correlated well with osteo-
sclerosis as seen on CT and with the areas accentuated
on the previous 99mTc bone scintigraphy study. A biopsy
from the tibial bone marrow was performed. Microscopic
examination of the specimen revealed thickened, irregular
bony trabeculae with numerous cement lines, insinuating
increased cellular turnover. The marrow itself was found
to be diffusely fibrotic with a small amount of residual fat
tissue and numerous macrophages which carry a CD68
(+), CD1a(-), S-100(-) immunohistochemical profile. Lang-
erhans cells and hematopoietic cells were not observed.
This picture was consistent with bone marrow involve-
ment of ECD. Following diagnosis in April 2013, the pa-
tient was tested for the V600E BRAF mutation and was
found to be negative. Steroids were introduced as a first
line treatment and later combined with vinblastine
(6 mg/m2/week) as a steroid sparing agent. This treat-
ment was administered for five months and subsequently
ceased due to progressive neurological deterioration. Sec-
ond line treatment with the pegylated form of interferon-α
(135 μg/week) was administered for two months yet failed
to halt this patient’s neurological deterioration. Ultimately,
the patient initiated treatment with cladribine IV (0.14 mg/
kg/day for five consecutive days, every four weeks). Follow-
ing four cycles of treatment a mild degree of radiological
improvement was noted on brain MRI. Nevertheless, no
clinical improvement was noted, neurological or otherwise.
Patients #4 and 5 - clinical analyses
In these patients, aside from their longstanding diabetes
insipidus, a well-known preceding sign of ECD, the initial
investigations eliciting symptoms were purely neuro-
logical, primarily cerebellar in nature, without any involve-
ment of bone pain. In both cases, a working diagnosis of
a possible histiocytic disorder was raised due to a high
index of suspicion, based on the clinical presentation,
longstanding diabetes insipidus and on the findings of
the brain MRI studies. These two patients exhibited a
rather interesting phenotype of ECD, restricted primarily
to the skeleton and central nervous system. Intracranially,
both suffered from meningiomas and involvement of
the ponto-cerebellar region. Nevertheless, a radiological
subclinical focus of disease was apparent only in the
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treatment, these patients exhibited a comparable response
pattern as well as a suboptimal outcome. It is likely that
higher dose interferon-α regimens may be necessary in
ECD patients with severe CNS involvement, as previously
documented by Hervier et al. [56].
Results
Seven patients (five men and two women) with biopsy
proven ECD were recruited from six medical centers in
Israel. The median age at the time of presentation was
53 years (range: 39 to 62 years). The median follow-up
time was 36 months (range: 1 to 72 months). Six of the
seven patients (86%) suffered from diabetes insipidus that
preceded the onset of investigation eliciting symptoms by
a median time of 87 months (range: 9 to 144 months).
The different presenting symptoms included bone pain
in 43% (three of seven) of the patients. This pain ranged
from mild (one patient) to severe (two patients). The pa-
tient who presented with mild bone pain originally
sought medical attention for relapsing remitting skin
lesions in outpatient settings. An atypical, painless pres-
entation characterized 43% (three of seven) of the patients,
who presented with worsening neurological symptoms
primarily of cerebellar nature (two patients) or with
renovascular hypertension (one patient). One patient (14%)
presented in the setting of an acute abdomen due to
perforation of his appendix by histiocytic infiltrate.
These different symptoms were accompanied by consti-
tutional symptoms, such as fever, malaise and fatigue in
all of the patients. Episodes of increased intracranial
pressure notable by papilledema were evident in 57%
(four of seven) of the patients. Preliminary complete
blood counts identified a microcytic anemia in 57%
(four of seven) of the patients, elevated levels of CRP in
43% (three of seven) and increased erythrocyte sedi-
mentation rate in 28.5% (two of seven).
Bone involvement was radiologically obvious in all of
the patients although bone pain ultimately affected only
57% (four of seven) of the patients. The bone lesions
were mostly of mixed lytic-sclerotic nature. In addition,
57% (four of seven) of the patients suffered from CNS
involvements of the disease associated with emerging
neurological symptoms. These intracranial involvements
included mostly lesions of the pons and cerebellum, but
also lesions of the cerebral hemispheres, venous sinuses
and meninges. The various clinical manifestations attrib-
uted to these lesions were ataxia, dysarthria, dysmetria,
dysdiadochokinesia and disturbance of balance. Retro-
orbital lesions caused exophthalmos in 43% (three of
seven) of the patients. A ‘hairy kidney’ appearance on
CT was identified in 71% (five of seven) of the patients.
However, renal function was preserved in all of the pa-
tients. Patient #1 exhibited the worst renal involvement,with severe hydronephrosis and marked thinning of the
cortex of the left kidney as well as compression of the
right kidney by an FDG uptaking mass on a PET/CT
scan. Skin lesions were noted in 57% (four of seven) of
the patients. These were periorbital yellowish xanthe-
lasma like lesions (three patients) and up to 8 mm in
diameter nodules of yellow-red color (one patient). Pul-
monary involvement was evident in 57% (four of seven)
of the patients. Two suffered from pleural effusions and
the other two exhibited mild thickening of the interlobu-
lar septae on CT. The mediastinum, heart and great
vessels were involved in 43% (three of seven) of the
patients. One example of cardiovascular involvement
was found in patient #3 who exhibited encasement of
the mediastinum and great vessels, lesions of the right
atrium and recurrent pericardial effusions which responded
to treatment with infliximab. Novel ophthalmological
findings were identified in patient #1, who exhibited an
infiltration pattern of the sub-choroidal layer on fundoscopy.
In order to confirm the diagnosis, an average count of
1.7 separate biopsies was required (range: one to three
biopsy sites), with a positive biopsy obtained from a long
bone source in 57% (four of seven) of the patients. Fifty
percent of the patients tested for the V600E BRAF muta-
tion (three of six) were found to harbor this particular
mutation. The different therapeutic agents used were
steroids, interferon-α, cladribine, vinblastine, methotrex-
ate, anakinra, infliximab and vemurafenib. Benefit from
treatment was considered as either normalization of the
constitutional symptoms, clinical improvement correlat-
ing with the relevant sites of involvement, radiological
evidence of lesion regression or a combination of these
three parameters. Interferon-α was beneficial in 50%
(three of six) of the patients treated. It is noteworthy
that the peri-renal, cardiovascular and intracranial in-
volvements proved to be rather refractory to treatment
with interferon-α at dosages below 6 × 106 IU X 3 times
weekly. Additionally, notable neurological improvement
was observed following treatment with vemurafenib in a
BRAF V600E positive patient. Regression of a substantial
pericardial effusion was observed following treatment
with infliximab and moderate reduction in the compres-
sion of intracranial perivascular sheathing (evident by
improved perfusion and imaging) was achieved after
treatment with cladribine.
Discussion
In the past three years, the constantly growing clinical
awareness of medical professionals has globally promoted
several substantial achievements in the evolution of ECD.
First, the rate at which patients are being diagnosed has
risen dramatically. Patients are being diagnosed much
earlier in the course of their disease. We now witness
subclinical, nearly asymptomatic ECD patients. Thus, new
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and risks of early medical interventions. Second, annual
ECD conferences are being held, promoting novel re-
search initiatives as well as the emergence of the first edi-
tion of consensus guidelines [53].
Nevertheless, the proper diagnosis and management of
an ECD patient remains a challenge. From our clinical
experience with seven patients, several key issues should
be addressed in the management of such patients. In
terms of diagnosis, as previously reported [81,38], dia-
betes insipidus of an unexplained etiology may precede
the onset of investigation eliciting symptoms by as many
as twelve years. Most peculiarly, the various anatomical
disruptions of the hypothalamic - pituitary regions that
could explain such a phenomenon appear on MRI, if at
all, months to years following diagnosis. This gap of time
suggests that the initial manifestations of ECD could in-
dolently progress from microscopic involvement which
generates a functional disturbance of the posterior pitu-
itary. Ultimately, this process may become evident on
MRI as absence of the high signal intensity of the poster-
ior pituitary on T1 weighted images or as thickening of
the pituitary stalk.
Another core issue relating to diagnosis of ECD is the
investigation eliciting symptom, which is most com-
monly bone pain. Complaints of diffuse long bone pain
of unexplained etiology in conjunction with a history of
diabetes insipidus should prompt a high index of suspi-
cion towards ECD. This suspicion may be further sub-
stantiated in the face of constitutional inflammatory
signs and symptoms, such as fever, malaise and in-
creased levels of ESR and CRP. The typical, symmetrical,
bilateral appearance of increased tracer uptake involving
the long bones on a 99mTc bone scintigraphy study
should prompt biopsies from high suspicion bone mar-
row foci for CD68(+), CD1a(-) histiocytes, a finding
which finalizes the diagnosis of ECD. Additionally, a
PET/CT scan may be useful in documenting extraskele-
tal involvements of ECD for the purposes of follow-up
or tissue acquisition. Occasionally, more than one biopsy
may be needed to successfully obtain a diagnostic speci-
men from a focus of interest. In many cases, the bone
marrow comprises a reasonable biopsy site. This is be-
cause it has proven reliable in the detection of the
typical tissue architecture that characterizes ECD on
pathological examinations, as well as the relative ease at
which immunohistochemical dyes are applied. However,
detection of the V600E BRAF mutation using PCR tech-
nology is more difficult to perform and yields less accur-
ate data when processed from a skeletal tissue source.
Conversely, favorable specimen sources for such an
examination are ECD skin lesions and the infiltrated
peri-renal fat that appears as a ‘hairy kidney’ on computed
tomography.Renal involvement is a common finding in ECD. In
their paper published in 2011, Haroche et al. report
from their clinical experience that 68% of their patients
were found to express a ‘hairy kidney’ appearance on im-
aging studies [5]. This radiological finding is typical of
peri-renal histiocytic infiltration among ECD patients.
Renal involvement in ECD should be a concern for the
managing physician, as peri-renal lesions may ultimately
lead to a post renal obstruction causing silent loss of a sin-
gle, or an apparent loss of both, kidneys [21]. Moreover,
peri-renal involvement in ECD may compromise the pa-
tency of the renal arteries due to external compression,
causing secondary renovascular hypertension and renal
failure [82]. Thus, frequent sonographic assessments of
the kidneys and ureters are advised for ECD patients
alongside ureteral stenting in selected cases.
The intracranial manifestations of ECD are diverse.
However, involvement of the cerebellum is frequent, par-
ticularly in the peri-dentate regions and in close proxim-
ity to the fourth ventricle. Radiologically, these lesions
may be heterogeneous in nature. It is noteworthy that
two of our seven patients exhibited multiple punctate
hypointensities in the basal ganglia in SWI sequence.
This pattern was never observed by us before in the con-
text of ECD. Yet another novel finding was that of an
ophthalmological involvement of ECD. In patient #1,
sub-choroidal lesions involving the macula densa ap-
peared on fundoscopy of both eyes and were better vis-
ible on red free imaging produced by a blue wavelength
confocal scanning laser ophthalmoscope. These findings
proved to be stable on a neuro-ophthalmological follow
up performed two years following their discovery. To
our knowledge, this is the first report of ECD-associated
retinal findings ever reported in the medical literature.
This subchoroidal infiltration pattern may contribute to
the understanding of the mechanisms involved in visual
disturbances in ECD. Disturbances of vision in ECD are
attributed to exophthalmos, increased intracranial pres-
sure and papilledema. It is plausible that interruption of
the visual fields and decreased visual acuity may origin-
ate in part due to a microscopic process involving the
retina. In the case of patient #1, the initial visual field
disturbances were attributed to increased intracranial
pressure while those that appeared later, were attributed
to these subchoroidal lesions.
Treatment wise, it is well established that interferon-α
should serve as the mainstay of therapy for ECD. In the
past, vinblastine was administered to ECD patients as a
single agent or in combination with interferon-α with
anecdotal reports of objective response [68,83]. Vinblast-
ine was considered primarily by analogy to the treatment
of Langerhans cell histiocytosis, potentially as a means
to augment the effect of interferon-α. However, of three
patients (#1,#3,#5) treated with vinblastine, only patient
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dose interferon-α.
Recent advances in the understanding of the molecular
biology underlying ECD have led to novel therapeutic
approaches to this disease. The accumulated data in the
literature strongly advocate that ECD is, in fact, a clonal,
neoplastic disorder originating from monocytic myeloid
blood components that exhibit prominent inflammatory
characteristics. A majority of these clones seem to be
predominantly driven by molecular elements involving
the RAS/RAF/MEK/ERK signal transduction pathway,
such as BRAF and NRAS, among others [50,84]. One
particular element identified in several large series, as
well as in ours, is the occurrence of the V600E BRAF
mutation in approximately 50% of the patients [50].
Nevertheless, the ability to accurately detect such gen-
etic alterations is subject to several limiting factors in-
cluding adequacy of samples, accuracy of the technology
used and the level of staff expertise in performing such
tests. For example, Cangi et al. report they were able to
detect the V600E BRAF mutation in all of the patients
evaluated in their cohort using the appropriate molecu-
lar techniques [85].
The pharmacological targeting of the V600E BRAF
mutation by the drug vemurafenib repeatedly yielded
dramatic clinical benefit in a significant portion of pa-
tients, unparallel to that of any other agent attempted in
the treatment of ECD. Evidently, this mutation should
be considered as a cardinal determinant in the thera-
peutic roadmap planning for ECD patients. From our
limited experience, we support vemurafenib as a second
line treatment agent for ECD patients who tested posi-
tive for the V600E BRAF mutation and failed to respond
to adequate doses of interferon-α.
BRAF negative patients should be offered the repertoire
of treatment alternatives according to the severity and dis-
tribution of their disease. In our series, interferon-α was
found to play a beneficial role in the treatment of the
skeletal manifestations of ECD. However, different pa-
tients in our series responded variably to interferon-α in
terms of the extraskeletal disease involvement sites and
the degree of lesion and symptom regression. A delicate
balance between toxicity and efficacy should be sought
in the dosage modulation of interferon-α, especially in
patients with cardiovascular and CNS disease localizations.Patient consent
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